NEO - התחייבויות לטווח ארוך להון NeoGenomics, Inc.

This chart illustrates that the market value of NeoGenomics, Inc. (NEO) is 0.56. The business relies on the B2B segment, providing genetic analysis for clinics and oncologists. Growth is driven by the implementation of advanced liquid biopsy systems and cost optimization. The technology stack is complemented by autonomous robotic manipulators that utilize AI to perform high-precision processing of biomaterials.

This indicator calculates the ratio of liabilities with a maturity of over one year to equity, providing a real-time assessment of the financial stability of NeoGenomics, Inc. (NEO). An optimal balance of this metric eliminates the risk of a credit rating downgrade, ensuring the resources necessary to develop a costly oncology diagnostics ecosystem. By analyzing the level of long-term debt relative to equity, investors evaluate the company's ability to fund the integration of proprietary tests into clinical protocols.